27-Feb-2026
Disc Medicine undergoes restructuring plan; slashes 20% of workforce
Seeking Alpha News (Fri, 27-Feb 5:28 PM ET)
Disc Medicine Implements Restructuring Following FDA Response
TipRanks (Fri, 27-Feb 5:22 PM ET)
Truist Financial Keeps Their Buy Rating on Disc Medicine (IRON)
TipRanks (Fri, 27-Feb 7:59 AM ET)
TipRanks (Fri, 27-Feb 7:50 AM ET)
Disc Medicine: Bitopertin’s De-Risked Path to Approval Supports Buy Rating
TipRanks (Fri, 27-Feb 6:25 AM ET)
TipRanks (Thu, 26-Feb 4:30 PM ET)
TipRanks (Thu, 26-Feb 4:15 PM ET)
Disc Medicine GAAP EPS of -$6.01
Seeking Alpha News (Thu, 26-Feb 10:13 AM ET)
Globe Newswire (Thu, 26-Feb 8:30 AM ET)
Disc Medicine’s RALLY-IBD Trial Puts a Spotlight on Anemia Relief in IBD Patients
TipRanks (Wed, 25-Feb 11:33 AM ET)
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Disc Medicine trades on the NASDAQ stock market under the symbol IRON.
As of February 27, 2026, IRON stock price declined to $66.62 with 229,057 million shares trading.
IRON has a beta of 1.46, meaning it tends to be more sensitive to market movements. IRON has a correlation of 0.16 to the broad based SPY ETF.
IRON has a market cap of $2.51 billion. This is considered a Mid Cap stock.
In the last 3 years, IRON traded as high as $99.50 and as low as $18.25.
The top ETF exchange traded funds that IRON belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
IRON has outperformed the market in the last year with a price return of +22.2% while the SPY ETF gained +18.5%. However, in the short term, IRON had mixed performance relative to the market. It has underperformed in the last 3 months, returning -28.9% vs +1.2% return in SPY. But in the last 2 weeks, IRON shares have fared better than the market returning +19.1% compared to SPY +0.6%.
IRON support price is $65.13 and resistance is $70.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRON shares will trade within this expected range on the day.